05:32 PM EDT, 06/11/2024 (MT Newswires) -- Nurix Therapeutics ( NRIX ) on Tuesday filed a registration statement with the US Securities and Exchange Commission covering the potential sale of its securities from time to time in one or more offerings.

The filing covers common stock, preferred stock, debt securities, warrants, subscription rights and units.

The company intends to use the net proceeds from the sale of securities for general corporate purposes, including funding research, clinical and process development, increasing working capital, debt repayment and possible future acquisitions.